Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Chinea Eziefula, Farrukh T Shah & Kofi A Anie. (2022) Promoting Adherence to Iron Chelation Treatment in Beta-Thalassemia Patients. Patient Preference and Adherence 16, pages 1423-1437.
Read now
Read now
Jane Vosper, Michael Evangeli, John B. Porter & Farrukh Shah. (2018) Psychological Factors Associated with Episodic Chelation Adherence in Thalassemia. Hemoglobin 42:1, pages 30-36.
Read now
Read now
Georgios N Lyrakos, Demetra Vini, Helen Aslani & Marouso Drosou-Servou. (2012) Psychometric properties of the Specific Thalassemia Quality of Life Instrument for adults. Patient Preference and Adherence 6, pages 477-497.
Read now
Read now
Articles from other publishers (14)
Fabio Tedone, Piero Lamendola, Stefania Lopatriello, Davide Cafiero, Daniele Piovani & Gian Luca Forni. (2021) Quality of Life and Burden of Disease in Italian Patients with Transfusion-Dependent Beta-Thalassemia. Journal of Clinical Medicine 11:1, pages 15.
Crossref
Crossref
Sherif M. Badawy, Amanda B. Payne, Mary M. Hulihan, Thomas D. Coates, Suvankar Majumdar, Dominic Smith & Alexis A. Thompson. (2021) Concordance with comprehensive iron assessment, hepatitis A vaccination, and hepatitis B vaccination recommendations among patients with sickle cell disease and thalassaemia receiving chronic transfusions: an analysis from the Centers for Disease Control haemoglobinopathy blood safety project. British Journal of Haematology 195:5.
Crossref
Crossref
Allen Shiun Chat Chai, Nani Draman, Siti Suhaila Mohd Yusoff, Nurul Fatihah Azman, Maryam Mohd Zulkifli, Najib Majdi Yaacob, Norsarwany Mohamad, Rosline Hassan, Wan Zaidah Abdullah & Bin Alwi Zilfalil. (2021) Non-compliance to iron chelation therapy in patients with transfusion-dependent thalassaemia. Pediatric Hematology Oncology Journal 6:4, pages 207-215.
Crossref
Crossref
Chia Chee Chong, Adyani Md Redzuan, Jameela Sathar & Mohd Makmor-Bakry. (2021) Patient Perspective on Iron Chelation Therapy: Barriers and Facilitators of Medication Adherence. Journal of Patient Experience 8, pages 237437352199695.
Crossref
Crossref
Farrukh Shah & Georgios Kaltsounis. (2018) Adherence to Treatment: Doctor vs Patient Perspective. Thalassemia Reports 8:1, pages 7484.
Crossref
Crossref
Meredith M Harvey, Karin G Coifman, Gail Ross, Dorothy Kleinert & Patricia Giardina. (2014) Contextually appropriate emotional word use predicts adaptive health behavior: Emotion context sensitivity and treatment adherence. Journal of Health Psychology 21:5, pages 579-589.
Crossref
Crossref
Manal Ibrahim Al-Kloub, Taghreed Nayel Salameh & Erika Sivarajan Froelicher. (2014) Impact of psychosocial status and disease knowledge on deferoxamine adherence among thalassaemia major adolescents. International Journal of Nursing Practice 20:3, pages 265-274.
Crossref
Crossref
Karin G. Coifman, Gail S. Ross, Dorothy Kleinert & Patricia Giardina. (2012) Negative Affect Differentiation and Adherence During Treatment for Thalassemia. International Journal of Behavioral Medicine 21:1, pages 160-168.
Crossref
Crossref
Mohamad H Qari, Yasser Wali, Muneer H Albagshi, Mohammad Alshahrani, Azzah Alzahrani, Ibrahim A Alhijji, Abdulkareem Almomen, Abdullah Aljefri, Hussain H Al Saeed, Shaker Abdullah, Ahmad Al Rustumani, Khoutir Mahour & Shaker A Mousa. (2013) Regional consensus opinion for the management of Beta thalassemia major in the Arabian Gulf area. Orphanet Journal of Rare Diseases 8:1.
Crossref
Crossref
Sheila A Fisher, Susan J Brunskill, Carolyn Doree, Onima Chowdhury, Sarah Gooding & David J Roberts. (2013) Oral deferiprone for iron chelation in people with thalassaemia. Cochrane Database of Systematic Reviews.
Crossref
Crossref
John Porter, Donald K. Bowden, Marina Economou, Jacques Troncy, Arnold Ganser, Dany Habr, Nicolas Martin, Adam Gater, Diana Rofail, Linda Abetz-Webb, Helen Lau & Maria Domenica Cappellini. (2012)
Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in
β
-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial
. Anemia 2012, pages 1-10.
Crossref
Crossref
John B. Porter, Michael Evangeli & Amal El-Beshlawy. (2011) The challenges of adherence and persistence with iron chelation therapy. International Journal of Hematology 94:5, pages 453-460.
Crossref
Crossref
P. J. Ho, L. Tay, R. Lindeman, L. Catley & D. K. Bowden. (2011) Australian guidelines for the assessment of iron overload and iron chelation in transfusion-dependent thalassaemia major, sickle cell disease and other congenital anaemias. Internal Medicine Journal 41:7, pages 516-524.
Crossref
Crossref
Felicia Trachtenberg, Elliott Vichinsky, Dru Haines, Zahra Pakbaz, Lauren Mednick, Amy Sobota, Janet Kwiatkowski, Alexis A. Thompson, John Porter, Thomas Coates, Patricia J. Giardina, Nancy Olivieri, Robert Yamashita & Ellis J. Neufeld. (2011) Iron chelation adherence to deferoxamine and deferasirox in thalassemia. American Journal of Hematology 86:5, pages 433-436.
Crossref
Crossref